Comparison of a twice-daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes.
CONCLUSIONS: Compared with BIAsp30, BIAsp50 showed greater efficacy in patients with baseline BG excursion >7.8 mmol/L or 2hPBG >17.6 mmol/L as well as good safety for hypoglycaemia.
CLINICAL TRIAL REGISTRATION: ChiCTR-IIR-16008958.
PMID: 30550344 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Insulin | Metformin | Research